Generic Name: moxetumomab pasudotox

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: AstraZeneca

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Lumoxiti is a CD22-directed toxin approved for adults with hairy cell leukemia that does not respond to prior treatment.

General Info

Lumoxiti is a cytotoxin that binds to the CD22 protein on B cells that grow out of control in certain types of leukemia. The toxin enters tumor cells and leads to cell death. A study showed an overall response rate of 75 percent and a complete response rate of 41 percent in patients with previously treated hairy cell leukemia. It was approved on September 13, 2018.


Dosing Info:

Lumoxiti is administered by intravenous infusion, usually on three days in a monthly cycle.

Side Effects

Common side effects include swelling, nausea, fatigue, headache, fever, constipation and diarrhea. More serious side effects may include kidney problems, infusion reactions and electrolyte imbalances. The Lumoxiti label includes a warning about capillary leak syndrome and hemolytic uremic syndrome, two life-threatening conditions caused by damage to small blood vessels.

For More Info:

Patient Assistance Program Info:

Last Reviewed: November 29, 2018